MANCHESTER, NH--(Marketwire - March 12, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrates to treat diabetes and inflammatory diseases, today announced that Peter Sheehan, M.D. has been appointed Consulting Medical Director.
Dr. Sheehan is an internationally respected specialist in the field of diabetes. Currently the President of Sheehan Health Management Consulting in New York City, he has been actively involved since 1990 in numerous clinical trials dealing with cardiovascular disease, wound healing, diabetic neuropathy and peripheral arterial disease, most recently as Senior Faculty, Mount Sinai School of Medicine. Dr. Sheehan also served as Associate Professor of Medicine, Clinical at New York University School of Medicine from 2002 to 2006, and as Assistant Clinical Professor of Medicine at SUNY Health Science Center from 1986 to 2002. Among his professional appointments, Dr. Sheehan is President of the NYC Leadership Council of the American Diabetes Association, a member of the Board of Directors of the Wound Healing Society and co-chair of the Peripheral Arterial Disease Coalition. He received his M.D. degree from SUNY-Downstate School of Medicine in 1981 and completed a research fellowship in 1986 at Yale University School of Medicine.
David Platt, Ph.D., Chief Executive Officer of Boston Therapeutics, said, "Peter brings a tremendous amount of clinical trial experience and innate ability to the Company, and we are very fortunate to have him serving as our Consulting Medical Director. Peter has immense insight into the challenges involved in the creation of novel treatments in the areas of diabetes and inflammatory disease, and we believe we will benefit significantly from his professional acumen and experience as we continue to develop our drug programs in these areas."
"Boston Therapeutics continues to serve as a leader in the use of complex carbohydrate chemistry to address unmet medical needs in the areas of diabetes and inflammatory diseases," commented Dr. Sheehan. "I am convinced of the need for ever-greater innovation in this area and I believe the diabetes epidemic is accelerating as lifestyles are changing. Boston Therapeutics is uniquely positioned to excel in this space. I look forward to serving as Consulting Medical Director and working with Boston Therapeutics' management as the Company moves ahead."
About Boston Therapeutics, Inc.
Boston Therapeutics, headquartered in Manchester, NH, (OTCQB: BTHE) is a pharmaceutical company focused on the development, manufacture and commercialization of novel compounds based on complex carbohydrate chemistry to address unmet medical needs in the areas of diabetes and inflammatory diseases. The Company's initial product pipeline is focused on developing and commercializing: PAZ320, entering a Phase lll clinical trial, is a non-systemic therapeutic compound designed to reduce post-meal glucose elevation, and IPOXYN™, an injectable anti-necrosis drug designed to treat ischemia. More information is available at www.bostonti.com.
Forward Looking Statements
Any statements in this news release about future expectations, plans and prospects for the Company constitute forward-looking statements as defined in the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those described in such statements.
More information about those risks and uncertainties is contained and discussed in the Company's most recent quarterly or annual report and in the Company's other reports filed with the Securities and Exchange Commission. The forward-looking statements represent the Company's views as of the date of this news release and should not be relied upon to represent the Company's views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company's views to change, the Company disclaims any obligation to update such forward-looking statements.